Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Incyte's skin disease drug meets main goal in late-stage study

Drugmaker Incyte said on Tuesday its cream to treat a type of skin disease met its main goal of improving skin clarity in patients with atopic dermatitis in a late-stage study.

Atopic dermatitis is a common chronic disease characterized by inflammation of the skin.

The study was testing the ruxolitinib cream in adolescent and adult patients aged 12 years and above.

(Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.